Implications of global pricing policies of pharmaceuticals for access the innovative drugs: the case of trastuzumab in seven Latin American countries
Differential pricing (DP) on the basis of countries’ purchasing power has been recommended by the WHO to secure more affordably priced medicines. However, in developing counties (DC) many innovative drugs have similar or even higher prices than in high-income countries (HIC). We conducted a cost-effectiveness (CE) analysis to estimate the impact of this pricing policy on the CE of trastuzumab in Latin-America (LA).
Autores:
Dr. Andrés Pichon-Riviere, Mag. Osvaldo Ulises Garay, MSc.Federico Augustovski, Dr. Carlos Vallejos, Dr. Leandro Huayanay, Mag. Ma. del Pilar Navia Bueno, Dr. Alarico Rodriguez, Mag. Cidley de Oliveira Guioti Dr. Carlos José Coelho de Andrade, Dr. Jefferson Antonio Buendía Rodríguez. Dr. Andrés Pichon-Riviere, Mag. Osvaldo Ulises Garay, MSc.Federico Augustovski, Dr. Carlos Vallejos, Dr. Leandro Huayanay, Mag. Ma. del Pilar Navia Bueno, Dr. Alarico Rodriguez, Mag. Cidley de Oliveira Guioti Dr. Carlos José Coelho de Andrade, Dr. Jefferson Antonio Buendía Rodríguez.
Tipo de publicación:
P. CIENTÍFICAS - Póster y Presentaciones